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Skin and Gut Microbiota in 
Psoriasis: A Systematic Review
Atiya Rungjang, Jitlada Meephansan and Hok Bing Thio
Abstract
Paying attention to a microbial approach may lead to improvements in diagnosis, 
treatment, prevention, and prognosis of psoriasis. A systematic review was per-
formed according to the PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines searching strategy to identify the pattern of the 
microbiome and the association of skin and gut microbiota with psoriasis, including 
the factors that may affect the results of the microbial study. In total, 16 studies were 
included in this systematic review. Ten studies investigated the skin microbiome, of 
which six studies were cross-sectional and four studies were prospective studies. Six 
studies investigated the gut microbiome, including five cross-sectional studies and 
one prospective study. The understanding of the relationship between microbiota 
and psoriasis may lead to diagnostics and treatment improvements. Currently, there 
is a slight consensus on some specific features that define psoriasis. However, no 
specific taxa have been identified as biomarkers of the disease, even from large-scale 
cohort studies. Thus, future cohort studies with standardized methodologies and 
proof-of-concept investigations in animal models may uncover the role of micro-
biota and the microbial pathways in psoriasis.
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1. Introduction
Psoriasis is one of the most common immune-mediated inflammatory skin 
diseases. The prevalence of the disease has been reported, with ranges from 0.09 to 
11.43% by the WHO Global Report 2016 [1]. Psoriatic skin lesions are characterized 
by hyperproliferation of keratinocytes, infiltration of immune cells, including neu-
trophils, T cells, dendritic cells, and macrophages. To date the etiology of this disease 
is not fully understood; genetic and environmental interaction plays a crucial role in 
the disease development [2, 3]. Recently, the immunological approach has helped to 
significantly clarify the pathophysiology of the disease. Dysregulation of both the 
bacteria, including Staphylococcus aureus [4], Streptococcus pyogenes [5], and fungi such 
as Malassezia [6] through innate and adaptive immune systems in genetically suscep-
tible individuals, such as immune cells in the skin, Tumor necrosis factor α, dendritic 
cells—particularly pathogenic T cells that produce high levels of IL-17 in response to 
IL-23, all contribute substantially to the pathogenic process [7].
Previous studies have indicated an association between psoriasis and numer-
ous comorbidities that share the chronic inflammatory state. Moreover, increasing 
evidence indicates that the gut microbe contributes to the onset of the low-grade 
inflammation, which is a pathological phenotype of these metabolic disorders [8].
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Additionally, it has been known that several microorganisms contribute to 
psoriasis exacerbation alterations in the innate and adaptive immune processes [9]. 
The increasing evidence here suggests that the microbiota may play a critical role 
in psoriasis pathogenesis. This systematic review aims to elucidate the correlation 
between the microbiome and psoriasis pathogenesis, and the microbiota modula-
tion that may lead to possible therapeutic interventions.
2. Psoriasis and microbiota
The initial search revealed a total of 629 studies of which 501 studies were 
excluded based on their title and abstract. The full texts were reviewed, and a fur-
ther 116 studies were excluded. An additional four studies from the reference lists of 
already included studies were included in the systematic review. In total, 16 studies 
were included in this systematic review; 10 studies investigated the skin microbi-
ome, of which 6 studies were cross-sectional and 4 studies were prospective study. 
Six studies investigated the gut microbiome, including five cross-sectional studies 
and one prospective study. The most commonly used method was 16S r RNA (skin 
swab, biopsies, curette); Langan et al. [10] used traditional culture combined with 
mass spectrometry (MALDI-TOF) (Table 1).
2.1 Skin microbiota in psoriasis
Several studies reported the characteristic features of microbiota in psoriatic 
skin (Table 2). Significant differences were observed between psoriatic lesion 
and control skin, but the changes were different in each study. Gao et al. [19] and 
Chang et al. [14] reported an increase in lesional skin diversity compared to non-
lesional and control. In contrast, subsequent studies by Fahlen et al. [18] found 
wider range of Shannon index values in the control suggesting that the trend of 
decrease in lesional psoriasis microbiome diversity is consistent with the findings 
by Alexseyenko et al. [17] who observed a decrease in the diversity and signifi-
cantly lower Shannon index in lesional skin. Consistent with previous studies, Tett 
et al. [16] found that psoriatic plaques at the ear are characterized by a significant 
decrease in microbial diversity. When beta diversity was analyzed to describe 
heterogeneity of microbial community, Fahlen et al. [18] reported a lower beta 
diversity in psoriasis compared to control, while Alexseyenko et al. [17] found that 
beta diversity was the highest in lesional skin, followed by unaffected skin, and the 
lowest in healthy skin. In line with the study by Tett et al. [16], which reported that 
ear lesions revealed higher beta diversity, Loeshe et al. [12] and Chang et al. [14] 
also reported a higher beta diversity at dry skin sites in psoriasis. At the phylum 
level, most skin bacterial composition fall into four major phyla: Actinobacteria, 
Firmicutes, Bacteroidetes, and Proteobacteria. Within these phyla, the three most 
abundant genera are: Propionibacterium, Corynebacterium, and Staphylococcus. 
From the studies of Gao et al. [19], Fahlen et al. [18], and Langan et al. [10], it has 
been revealed that at the phylum level, compared to healthy skin, psoriatic skin was 
associated with an increase in the relative abundance of Firmicutes but a decrease 
for Actinobacteria, which is partially consistent with Alexseyenko et al. [17] who 
identified psoriatic lesion as cutaneo type 2, which was dominated by Firmicutes 
and Actinobacteria. In contrast, Firmicutes were lower in the studies by Loeshe et al. 
[12], Assarsson et al. [13], and Drago et al. [15]. Proteobacteria showed inconsistent 
abundance, lower in lesional skin as observed by Gao et al. [19] whereas Fahlen 
et al. [18] observed an increase, and Drago et al. [15] reported that Proteobacteria 
and Bacteroidetes were the dominant microbiota in psoriasis lesion. At the genus 
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Study Study design/
ratings of the 
quality
Population Result
Langan et al. 
[10] (2019)
Cross-
sectional/4
23 Pso, 20 C Pso L
At the phylum level:
↑ Firmicutes, ↓Actinobacteria
At the genus level:
↑Prevotella, Staphylococcus, ↓Anaerococcus and 
Propionibacterium
Prevotella and Staphylococcus significantly 
associated with Pso L
Pso NL
↑Anaerococcus, Propionibacterium
Prospective 
systemic 
treatment/2
Actinobacteria-to-Firmicutes ratio, partially 
reversible during treatment
Biological therapies demonstrated the largest 
impact on the ratio of Actinobacteria to Firmicutes
Corynebacterium, Staphylococcus, significantly 
correlated with PASI scores
Stehlikova 
et al. [11] 
(2019)
Cross-
sectional/4
34 Pso, 25 C Beta diversity: no significant differences between 
Pso L and Pso NL
Pso L
↑ Streptococcus regardless of the sampling site
↑ Brevibacterium richness and evenness in in the 
elbow lesions, compared to back lesions
↓Propionibacterium PsoL, PsoNL compared C in 
elbow lesions
Remark
Alpha diversity and bacterial taxa from skin swab, 
scraping, and biopsy are comparable
Loesche et al. 
[12] (2018)
Remark: 
study did 
not include 
healthy 
control
Cross-
sectional/4
114 Pso Beta diversity: Pso L > Pso NL
Pso L
At the phylum level: ↑Actinobacteria in leg, scalp, 
and trunk lesions ↓Firmicutes in scalp and trunk 
lesions
At the genus level: ↓Caulobacteraceae, 
Corynebacterium leg lesions
At the species level: ↑Bacilli↓Propionibacterium 
acnes in scalp lesions
Streptococcus colonization of skin does not correlate 
with severity in lesional and non-lesional skin
Longitudinal 
RCT/1
89 Pso Pso L and Pso NL respond similarly to ustekinumab
Significant change in abundance from baseline in 
all body sites
No difference diversity in Pso L vs. Pso NL except 
↑ in trunk
Pso L microbiota was not converging with Pso NL 
as treatment progressed
Microbiota diverged further between Pso L and Pso 
NL across body sites
Assarsson 
et al. [13] 
(2018)
Remark: 
study did 
not include 
healthy 
controls
Cross-
sectional/4
26 Pso Pso L
↓Firmicutes Staphylococcus
Longitudinal 
Narrowband 
UVB/2
Pso L
↓Firmicutes, Staphylococcus, Finegoldia, 
Anaerococcus, Peptoniphilus, Gardnerella, Prevotella, 
Clostridium
Pso NL
↓Firmicutes
↓Pseudomonas in treatment responders
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Study Study design/
ratings of the 
quality
Population Result
Chang et al. 
[14] (2018)
Cross-
sectional/4
28 Pso, 26 C Alpha diversity: Pso L > Pso NL > C
↑ Beta diversity in all dry skin sites
Psol L
↑ Alpha diversity at dry skin sites, with a trend at 
the sebaceous (scalp) site, and no increase at moist 
sites
↑S. aureus and S. pettenkoferi
Pso NL
↑S. sciuri
C
↑P. acnes, P. granulosum
Drago et al. 
[15] (2016)
Cross-
sectional/4
3 adult first 
cousins— 
1 AD, 1 Pso, 
1 C (same 
lifestyle and 
environmental 
factors)
Pso L
At the phylum level
↓ Firmicutes, ↑ Proteobacteria in Pso L compare to 
AD and C
At the family level
↑ Streptococcaceae, Rhodobacteraceae, 
Campylobacteraceae, Moraxellaceae in Pso L 
compare to AD and C
↓Staphylococcaceae, Propionibacteriaceae in Pso L 
compare to AD, C.
At the species level: ↓ Propionibacterium acnes in 
Pso compare to AD and C.
↓ S. aureus in Pso L < C < AD, no difference in Psp NL
Tett et al. [16] 
(2017)
Remark: 
study did 
not include 
healthy 
control
Cross-
sectional/4
28 Pso Alpha diversity: Pso L < Pso NL in ear lesions 
(richness did not correlate with PASI score)
Beta diversity: Pso L > Pso NL in ear lesions
Pso L
At the phylum level:
Actinobacteria and Firmicutes.
At the genus level:
Staphylococcus
At the species level:
S. epidermidis, P. acnes, S. caprae/capitis, and M. luteus
Alekseyenko 
et al. [17] 
(2013)
Cross-
sectional/4
75 Pso, 124 C Alpha diversity: Pso L < Pso NL and C
Beta diversity: Pso L > Pso NL > C.
Pso L
At the phylum level:
Cutaneotype 2 (dominated by Actinobacteria, 
Firmicutes)
At the genus level:
↑ combined relative abundance of Corynebacterium, 
Propionibacterium, Staphylococcus, Streptococcus
↓Cupriavidus, Flavisolibacter, Methylobacterium, 
Schlegelella.
At the species level:
Acidobacteria, Schlegelella
Acidobacteria positively correlated with PASI
C:
Cutaneotype 1 (dominated by Proteobacteria)
↓ Cupriavidus, Flavisolibacter
Longitudinal 
12 weeks, 
36 weeks 
after systemic 
treatment/1
17 Pso, 15 c No statistically significant difference was observed 
between the lesion and unaffected groups, or 
longitudinally within groups
Pso L
↑Relative abundance of Corynebacterium, 
Propionibacterium, Staphylococcus and Streptococcus
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level, Streptococcus were higher in lesional skin by Gao et al. [19], Fahlen et al. [18], 
Alexseyenko et al. [17], Stehlikova et al. [11], and Drago et al. [15] while Loeshe 
et al. [12] found no correlation between psoriasis lesional and unaffected skin. 
Staphylococcus were detected more frequently in the lesion by Gao et al. [19] and 
Tett et al. [16] opposite to Fahlen et al. [18] who found that Staphylococcus were 
increased in abundance in healthy controls. Lower abundance of Propionibacterium 
in lesional skin was reported by Gao et al. [19], Fahlen et al. [18], Drago et al. [15], 
Stehlikova et al. [11], and Loeshe et al. [12], which is in contrast to Alexseyenko 
et al. [17] who reported an increase in the relative abundance of combined 
Gram positives such as Corynebacterium, Propionibacterium, Staphylococcus, 
and Streptococcus. In the subsequent study by Langan et al. [10], the presence of 
Corynebacterium and Staphylococcus was found to be significantly correlated with 
PASI scores while Anaerococcus and Propionibacterium were associated with non-
lesional skin. These are consistent with the reports by Gao et al. [19] and Chang 
et al. [14] that at species level lesional skin psoriasis had an increased level of S. 
aureus but a decreased level of P. acne. On the other hand, study on the importance 
of site-specific microbiota without related disease reported that at the species level 
the most abundant bacteria were S. epidermidis and P. acne irrespective of disease 
status and hence suggested that an underlying subject-specific microbial signature 
better defines the microbiome.
There is a challenge to identify the explicit features of healthy or psoriasis micro-
biomes. Investigations of such a complex system of bacteria, fungi, and viruses are 
difficult and there is also high variation between samples. The composition of these 
communities of microorganisms depends on skin characteristics, such as sebaceous 
gland concentration, moisture content, topography, and temperature, as well as on 
host genetics and exogenous environmental factors [20]. Thus, the skin microbiome 
is biogeographically specific for each body site [21]. Demographic differences, such 
as gender, age, place of residence, living with animals, hygiene habits, occupation, 
and ethnicity also influence the composition of the skin microbiome [22]. The 
underlying disease and/or disease severity may also have an effect on the microbi-
ome diversity or alterations in microbial communities due to disease states.
Study Study design/
ratings of the 
quality
Population Result
Fahlen et al. 
[18] (2012)
Cross-
sectional/4
10 Pso, 12 C Alpha diversity: no difference observed when using 
the Shannon index
Beta diversity: Pso L < C
Pso L
At the phylum level: ↓ Actinobacteria, ↑ 
Proteobacteria in trunk lesions
At the phylum level:
↓ Propionibacterium in all sites, ↓Staphylococcus
↑Streptococcus/Propionibacterium ratio
Gao et al. [19] 
(2008)
Cross-
sectional/4
6 Pso, 6 C Alpha diversity: Pso L > Pso NL, C
Beta diversity: Pso L > C
At the phylum level: ↑ Firmicutes, ↓ Actinobacteria, 
Proteobacteria
At genus level: ↓ Propionibacterium, ↑ Streptococcus
At the species level:
↓ P. acne, ↓ Anaerobic species
Pso—Psoriasis, C—Control, Pso L—Psoriasis lesional skin, Pso NL—Psoriasis non-lesional skin.
Table 1. 
Skin microbiota in patients with psoriasis.
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Moreover, microbiome diversities differ between studies; however, the more 
recent studies demonstrate decreased alpha diversity with increased beta diversity 
in psoriasis. Also, there are data that demonstrate a trend toward a changing 
microbial composition in psoriasis-affected skin. Propionibacterium is known as a 
protective commensal bacterium that is related with SCFA and propionate pro-
duction, which regulates immune function. The decrease in the relative abundance 
of this microorganism in psoriasis may be related to the course of disease. In most 
studies, Staphylococcus are dominant in psoriatic skin, as species such as S. aureus 
proposed pathogenic Th17 activation while S. epidermidis appear to modulate 
immune and barrier functions. Interestingly, a study by Tett et al. [16] reported  
Finding By
Alpha diversity Increased Gao et al. [19], Chang et al. [14]
Decreased Fahlen et al. [18], Alexseyenko et al. 
[17], Tett et al. [16]
Beta diversity Lower Fahlen et al. [18]
Highe Alexseyenko et al. [17], Tett et al. [16], 
Loeshe et al. [12], Chang et al. [14]
Phylum level
Firmicutes Increased Firmicutes Gao et al. [19], Fahlen et al. [18], 
Langan et al. [10]
Decreased Firmicutes Loeshe et al. [12], Assarsson et al. 
[13], Drago et al. [15]
Actinobacteria Decreased Actinobacteria Gao et al. [19], Fahlen et al. [18], 
Langan et al. [10]
Increased Firmicutes and Actinobacteria Alexseyenko et al. [17]
Proteobacteria Decreased Proteobacteria Gao et al. [19]
Increased Proteobacteria Fahlen et al. [18], Drago et al. [15]
Genus level
Streptococcus Increased Streptococcus Gao et al. [19], Fahlen et al. [18], 
Alexseyenko et al. [17], Stehlikova 
et al. [11], Drago et al. [15]
No correlation Loeshe et al. [12]
Staphylococcus Increased Staphylococcus Gao et al. [19], Tett et al. [16]
Decreased Staphylococcus Fahlen et al. [18]
Propionibacterium Lower Propionibacterium Gao et al. [19], Fahlen et al. [18], 
Drago et al. [15], Stehlikova et al. 
[11], Loeshe et al. [12]
Gram positives Increased relative abundance of combined 
Gram positives: Corynebacterium, 
Propionibacterium, Staphylococcus, and 
Streptococcus
Alexseyenko et al. [17]
Corynebacterium and Staphylococcus were 
significantly correlated with PASI scores
Langan et al. [10]
Increased S. aureus, decreased P. acne Gao et al. [19]
Site-specific microbiota without related 
disease
Tett et al. [16]
Table 2. 
Summary of skin microbiota findings in psoriasis.
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S. epidermidis strains contain known virulence-related genes that are predominate 
in psoriasis-affected skin. Therefore, a future study at the species and the strain 
level may provide more information.
2.2 Gut microbiota in psoriasis
The fecal sample study by Scher et al. [27] revealed that gut microbiome in 
skin psoriasis and psoriatic arthritis had a decrease in alpha diversity compared to 
control, and Actinobacteria had a decrease in relative abundance at the phylum level. 
This is in line with Masallat et al. [28] who found that the relative abundance of 
Actinobacteria was reduced in psoriasis versus healthy controls with a negative cor-
relation of PASI score whereas the ratio of Firmicutes to Bacteroidetes was positively 
correlated with PASI score. This is consistent with Codoner et al. [25] who found a 
lower abundance of Bacteroides at the genus level and characterized core microbiome 
of psoriasis by an increase in Feacalibacterium but a decrease in Bacteroides spp. The 
abundance of Akkermansia, Ruminococcus, and Pseudobutyrivibrio was found to be 
lower in psoriatic arthritis compared to controls by Scher et al. [27]. Eppinga et al. 
[29] found that the abundance of Faecalibacterium prausnitzii was reduced in psoria-
sis with a significant increase in the relative abundance of Escherichia coli (Table 3).
The gut is considered as a major immune organ, with gut-associated lymphoid 
tissue (GALT) being the most complex immune compartment [30]. It is well known 
that change in the microbe composition may promote both health and disease [31]. 
Intestinal dysbiosis has been implicated in the etiology of various diseases [32], 
such as Crohn’s disease and obesity [33, 34]. Moreover, there is strong evidence 
that indicates intestinal dysbiosis is clinically relevant to psoriasis [35, 36]. The 
importance of the gut-skin axis in the pathogenesis of psoriasis has recently been 
documented in humans, as well as in animal models of psoriasis [9, 37]. A study 
by Tan et al. identified that the signature of gut microbiota and its function are 
significantly altered in the gut of patients with psoriasis [24]. Intestinal and skin 
microbiota directly regulate imiquimod-induced skin inflammation (IISI), and 
emphasizes the importance of microbiota in the pathogenesis of psoriasis [38]. A 
study by Zákostelská et al. has shown that exposure of mice to antibiotics inhibited 
the induction of psoriasis [37].
To identify bacterial pathways, which may be involved in the pathogenesis of 
psoriasis, it should be highlighted that SCFAs potentially regulate the generation 
and function of Th17 cells [39]. Moreover, in psoriasis the loss or depletion of 
Faecalibacterium prausnitzii, a major source of the protective SCFAs in the gut, 
may be associated with disease development [29]. In psoriatic arthritis, decreased 
Akkermansia and Ruminococcus, which are protective bacteria that regulate the 
intestinal barrier that produces SCFA, may be related with disease severity. Gut 
dysbiosis markedly reduced butyrate production, which inhibits NF-ĸβ, an inflam-
mation pathway that impacts gut epithelial integrity and consequential cross-talk 
between gut proteins, bacteria, and the innate and humoral immune systems [23]. 
Alterations in the pathways involved in LPS function were also observed in psoriasis 
patients. Additionally, LPS is also thought to be involved in gut inflammation and 
has been linked to the pathogenesis of insulin resistance and diabetes mellitus 
[40], which has been epidemiologically associated with psoriasis. A decrease in 
Bacteroides, which are known to play an immunomodulatory role in the gut through 
the production of polysaccharide A that induces regulatory T cells, may result in 
an altered immune response [41]. Whereas a decrease in Actinobacteria, a phylum 
that includes the Bifidobacterium species that have been shown to reduce intestinal 
inflammation, suppresses autoimmunity, and induces regulatory T cell expression. 
There are also several studies that have shown how bacterial translocation from the 
Human Microbiome
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Study Study design/
ratings of the 
quality
Population Result
Shapiro et al. 
[23] (2019)
Cross-sectional/4 24 Pso 22 C Alpha diversity, beta diversity: no 
significant differences
At the phylum level: ↑Firmicutes, 
Actinobacteria
↓Bacteroidetes, Proteobacteria
At the species level:
↑Ruminococcus gnavus, Doreaformici 
generans and Collinsella aerofaciens, 
Prevotella copri and Parabacteroides 
distasonis
Tan et al. [24] 
(2018)
Cross-sectional/4 14 Pso 14C Pso L
At the phylum level: 
↓Verrucomicrobia, Tenericutes
At the class level: ↓Mollicutes, 
Verrucomicrobiae
At the order level: 
↓Verrucomicrobiales, RF39
At the family level: 
↓Verrucomicrobiaceae, S24–7
At the genus level: ↑Bacteroidaceae, 
Enterococcaceae, ↓Akkermansia
At the species level: ↓Akkermansia 
muciniphila, ↑Clostridium 
citroniae
Codoner et al. 
[25] (2018)
Remark: study 
did not include 
healthy control
Cross-sectional/4 52Pso compared with 
a cohort of over 300 
healthy individuals 
extracted from the 
human microbiome 
project
Pso:
↑Beta diversity
Enterotype 2 (predominance of 
Prevotella) tended to experience 
more frequent bacterial translocation 
and higher inflammatory status
↓Bacteroides, ↑Akkermansia, 
Faecalibacterium
Chen et al. [26] 
(2018)
Cross-sectional/4 32Pso 64 C Diversity: no significant difference 
between Pso and C
At the phylum level: ↑Firmicutes, 
↓Bacteroidetes
At the genus level: ↑ Ruminococcus, 
Megasphaera
At the family level: ↓Bacteroidaceae, 
Prevotellaceae ↑ Ruminococcaceae, 
Lachnospiraceae
Other covariates: sex, disease 
activity assessed by PASI score, 
phototherapy, arthritis, as well 
as diet, alcohol, smoking, coffee, 
tea, and habit of exercise, did not 
significantly affect the abundance 
profile of intestinal microbiota 
among Pso and C
Patients receiving 
systemic 
treatment 
(DMARDs or 
biologics drugs 
BioSysDrug) 
subgroup 
analyses /2
20 Pso ↓the species Prevotella stercorea, 
belonging to Prevotellaceae, of the 
phylum Bacteroidetes, in patients 
receiving BioSysDrug
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gut and skin into the bloodstream may take place in psoriasis, and be responsible for 
driving the chronic, systemic inflammatory nature of the disease [42].
2.3 Skin mycobiota
An investigation by Findley et al. suggests that fungal diversity is increased in 
psoriatic lesions, compared to healthy skin sites. Furthermore the skin of psoriatic 
patients, at the genus level, is dominant with Malassezia [43]. Whereas the study by 
Takemoto et al. found that psoriatic skin revealed higher diversity and decreased 
relative abundance of Malassezia, which is still the most abundant phylum com-
pared to controls. Moreover, the ratio of M. globosa to M. restricta is lower in psori-
atic lesions [44]. Stehlikova et al. [11] found no significant difference in alpha and 
beta diversity and a significant increase in abundance of M. restricta in back lesions 
and M. sympodialis in the elbow lesions. Conversely, however, Paulino et al. showed 
that psoriatic lesions on the back, in decreasing order of abundance, are predomi-
nated by M. restricta, followed by M. globosa and M. sympodialis, respectively. 
Paulino et al. concluded that there was no significant difference between the fungal 
compositions of psoriatic and healthy skin [45]. Furthermore, Paulino et al. also 
showed there was no consistent variation between psoriasis and healthy controls 
[46] as M. furfur was found only in the skin of psoriasis participants in the study by 
Jagielski et al. [47] compared to healthy controls and atopic dermatitis.
2.4 Factors affecting microbiota study
So far, no specific patterns of microbiota in psoriatic patients have been identi-
fied (Tables 1 and 3).
The difficulty to establish such precise features, although a plethora of pub-
lished studies have attempted to do so, is due to the lack of standardized protocols. 
Differences in sample collection and processing, sequencing methods, and analysis 
procedures between studies may impact the study results [48], and can confound 
comparisons and results in incompatible outcomes (Table 4).
Study Study design/
ratings of the 
quality
Population Result
Scher et al. [27] 
(2015)
Cross-sectional/4 15Pso, 16PsA 17C Diversity: Pso, PsA < C
At the phylum level:
↓Firmicutes, Clostridiales, 
Verrucomicrobiales
↑ Bacteroidetes in PsA vs. Pso
↓Actinobacteria in Pso vs. C
At the genus level:
↓Coprococcus spp. in Pso and PsA 
vs. C
↓Akkermansia, Ruminococcus, 
Pseudobutyrivibrio in PsA vs. C
↓Parabacteroides, Coprobacillus in 
Pso vs. C
Masallat et al. 
[28] (2016)
Case control/4 45Pso 45C ↑Firmicutes/Bacteroidetes ratio 
correlated with PASI
↓Actinobacteria
Pso—Psoriasis, C—Control, Pso L—Psoriasis lesional skin, Pso NL—Psoriasis non-lesional skin.
Table 3. 
Gut microbiota in patients with psoriasis.
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Different factors that may affect microbiome study
• Host factors: Not many studies accounted the interpersonal and intrapersonal 
factors that affect the microbial community.
• Samples collected from different body sites cannot be compared due to site-
specific niches, as described previously [21].
• Sampling method: Several studies showed that different skin layers contain 
different bacterial communities [48]. Most of the published research on 
cutaneous microbiota has been based on skin swabs, which represent the 
surface of the skin. Prast-Nielsen et al. [49] found differences in both diver-
sity and taxonomic composition of the microbiome obtained from swabs 
and biopsies of the same individual, while an investigation by Stehlikova 
et al. showed that various sampling approaches (swab, scraping, and biopsy) 
in affected and unaffected skin of psoriatic patients and in healthy control 
skin results in similar bacterial diversity despite the different genera abun-
dance that is observed [11]. Grice et al. used three different sampling strate-
gies in the antecubital fossa of five patients: swabs, skin scrapes, and punch 
biopsies, and concluded that similar microbial populations were captured by 
each technique and that the dominant species was present in the noninvasive 
swabs [50]. Recent studies have also reported that the tape stripping method 
may capture more viable bacteria than the swabbing method [51].
Sequencing methods, analysis procedures, and techniques for studying the 
microbiome:
• Langan et al. demonstrated that the changes in the microbiome during treat-
ment that were detected by 16S rRNA were not detected by culture data. This 
suggested that changes in bacterial populations may have been too subtle to 
be detected by culture, or that changes are predominantly in nonculturable 
species [10].
• Studies using the most often used 16S rRNA have shown that the accuracy of 
molecular signatures depends on DNA sequencing and downstream analysis 
protocols. Therefore numerous combinations of primer pairs have been previ-
ously tested to select the most appropriate one for skin microbiome surveys; 
however, standardized methodology is still lacking [52].
 ○ Several studies suggested that primers for V1V3 and V3V4 hypervariable 
regions were described to sufficiently cover the skin bacterial diversity [20].
Findings By
Alpha diversity Decreased Scher et al. [27]
Actinobacteria Decreased Scher et al. [27], Masallat et al. [28]
Bacteroides Lower Codoner et al. [25], Masallat et al. [28]
Feacalibacterium Increased Codoner et al. [25]
Table 4. 
Summary of gut microbiota findings in psoriasis.
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 ○ Statnikov et al. concluded that using 16S rRNA data from the V3–V5 locus 
leads to accurate and statistically significant molecular signatures, whereas 
data from the V1–V3 locus carry a limited diagnostic signal [53].
 ○ The latter study by Stehlikova et al. observed that variable regions of the 
V3V4 region capture a wider microbial diversity than the V1V2 region, where 
observed and estimated richness was significantly higher when using the 
V3V4 region compared to the V1V2 region [11].
• Whole-genome shotgun metagenomics offers the most comprehensive and 
robust data; however, as a result of its high cost, only a few shotgun metage-
nomic studies have been conducted on the microbiota associated with the skin, 
such as the Human Microbiome Project [54]. We found very few studies on 
psoriasis microbiome.
2.5 Therapeutic implements
Several studies reveal that psoriasis treatment changes the gut and skin micro-
biome, such as the correlation between psoriasis systemic treatment and the 
Actinobacteria-to-Firmicutes ratio. Biological therapies demonstrated the largest 
impact [10] during ustekinumab treatment; the composition of microbiota diverged 
further between lesional and non-lesional skin, across body sites, which could 
be due to the regression of lesions that returns the skin to more normal environ-
ments and increases the body site-specific niches [12]. Secukinumab (anti-IL17) 
therapy is associated with distinct and more profound gut microbiome shifts than 
ustekinumab therapy (anti-IL 12/23), in patients with psoriasis by increasing the 
relative abundance of Proteobacteria and decreases in Bacteroidetes and Firmicutes 
[55]. Burns et al. demonstrates that UVR has profound qualitative and quantitative 
influences on the composition of the skin microbiome by an increase in the phylum 
Cyanobacteria and a decrease in the family Lactobacillaceae and Pseudomonadaceae 
[56]. This suggests that skin microbiome alterations after UVB treatment could be 
related to treatment and treatment responses [13]. Thus, it may be implied that the 
modulation of the gut and skin microbiota can improve disease condition.
Therapeutic modalities that target the shifting microbiota:
The use of orally administered antibiotics, prebiotics, probiotics, and most 
recently, fecal transplantation [57] also appears to improve the disease condition 
and may be a practical prospect as a therapeutic avenue.
• Antibiotic treatment of psoriasis can alter the bowel flora toward normality, and 
therapy might include the use of appropriate antibiotics to reduce susceptible 
microbes while permitting others to flourish [58]. Saxena and Dogra reported 
that administration of benzathine penicillin in psoriasis vulgaris patients showed 
a significant improvement [59] and administration of azithromycin revealed a 
significant improvement at 12 weeks in the patient with psoriasis [60].
• Pro- and prebiotics are commonly used to modulate the microbiome by 
promoting the growth of specific species. Three studies using three distinct 
probiotic species affecting distinct pathways of the pathomechanism of 
psoriasis [61, 62] have all shown improvement in the course of the disease. 
The probiotics resulted in the improvement of epithelial barrier function, 
increased production of TNF-alpha by epithelial cells, and regulated activa-
tion of the NF-ĸβ pathway [63]. An issue with probiotic supplementation is 
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that the colonization of probiotic bacteria in the gut is mostly transient as 
they are only detectable for less than 2 weeks after cessation of intake [64]. 
However, a study by Maldonado-Gómez et al. demonstrated that a certain 
Bifidobacterium longum (B. longum) strain was able to persist for over 6 months 
in a subset of subjects where it was originally absent [65]. A recent, random-
ized, double-blind, placebo-controlled trial evaluated the effect of a probiotic 
mixture as co-adjutant treatment together with topical steroids in 90 patients 
with plaque psoriasis. The results showed a large reduction in the score of 
severity indexes in the probiotic group, compared with the placebo group. Gut 
microbiota analysis demonstrated the efficacy of the probiotic in modulation 
of the composition of the microbiota. After the end of the probiotic or placebo 
intake, patients were followed up for 6 months. The results showed a lower risk 
of relapse in patients in the probiotic group [66].
• Topical probiotics show that after sequential applications of a donor microbi-
ome, the recipient microbiome becomes more similar to the donor [67]. The 
use of topical probiotics may have special subclinical significance, for example, 
to improve skin defense with probiotic-containing cosmeceuticals. It has been 
reported that B. longum strains exert pro-differentiating, as well as and pro-
regenerating, effects on primary human epidermal keratinocytes [68]. Thus, 
using the most suitable oral probiotic strain in combination with topical probiot-
ics and/or prebiotics might help in the personalized treatment of skin disorders.
• Fecal microbiota transplantation (FMT) is currently being used to restore the 
balance of the intestinal microbiota [69, 70]. Particularly, this procedure has 
demonstrated >90% clinical resolution of recurrent, or refractory, Clostridium 
difficile infections [71]. Also, multiple FMTs seem to be able to induce remission 
in patients with IBD [72]. Due to these results, FMT is now being tested as a 
potential novel treatment for other gastrointestinal and extraintestinal diseases 
[73] as it greatly improves outcomes compared with those before treatment.
3. Conclusion
The function of microbiota may be more important in psoriasis. The metabolic 
activity of microbiota may become an upcoming research area in near future for 
identifying crucial biomarkers and new therapeutic approaches for psoriasis. 
Future cohort studies with standardized methodologies and proof-of-concept inves-
tigations in animal models may uncover the role of microbiota and the microbial 
pathway in psoriasis. This, then, may lead to the development of diagnostics and 
therapeutic opportunities.
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